Sumitomo Chemical Company, Limited
FY2026 Third Quarter Financial Summary [IFRS] (Consolidated)
For the third quarter of FY2026, revenue amounted to JPY 1,706.3 billion (down 10.4% YoY), net income attributable to owners of the parent was JPY 87.4 billion (up 254.2% YoY), the full-year earnings guidance has been revised upward, and the annual dividend forecast was increased to JPY 13.5 per share.
Key Figures
- Revenue: JPY 1,706.3 billion (down 10.4% YoY)
- Net Income Attributable to Owners of Parent: JPY 87.4 billion (up 254.2% YoY)
- Annual Dividend Forecast: JPY 13.5 (Increased from previous forecast)
AI要約
Overview of Results
Consolidated revenue for the third quarter of FY2026 decreased by JPY 198.5 billion YoY to JPY 1,706.3 billion. On the profit and loss front, core operating income rose significantly to JPY 186.8 billion (up 211.1% YoY), operating income increased to JPY 180.4 billion (up 24.1% YoY), and net income attributable to owners of the parent grew markedly to JPY 87.4 billion (up 254.2% YoY). By segment, Sumitomo Pharma increased revenue by JPY 53.6 billion to JPY 346.4 billion, and core operating income rose by JPY 86.9 billion to JPY 111.2 billion. Conversely, Essential & Green Materials saw revenue decline by JPY 161.9 billion to JPY 511.0 billion, but core operating income improved by JPY 64.1 billion to JPY 19.8 billion.
Outlook and Dividend
The full-year consolidated earnings guidance for FY2026 has been revised upward with revenue expected to be in the JPY 2.3 trillion range (from JPY 2.3 trillion), and core operating income raised from JPY 185 billion to JPY 200 billion. Operating income and net income attributable to owners of the parent are also expected to increase, with net income forecast raised from JPY 450 billion to JPY 550 billion. Accordingly, the annual dividend forecast has been increased to JPY 13.5 per share. The capital structure has strengthened, with the parent owners' equity ratio rising to 29.3%.
